ClinicalTrials.gg
TerminatedNCT01760993Updated Jun 22, 2021Results posted

Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia

A Phase 3 interventional study of SPD489 in Schizophrenia, sponsored by Shire. Terminated at 2 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-06-22.

Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment

Why this study was terminated
Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Schizophrenia by Takeda — none open to participants now, none under way, none of them phase 3. Schizophrenia · Takeda.

Enrollment
9th of 11
2 · median 20
Started
2013
with 3 others
Phase 3
4 of 11
none open now
Registered
5th of 11
by date

Among the 11 studies in Schizophrenia by Takeda, this one is the 9th largest by enrollment, is one of 4 that started in 2013, is one of 4 in phase 3, and was the 5th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

None of the 11 studies in Schizophrenia by Takeda is open now. The open studies under Schizophrenia, anywhere →

Where they have run

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Schizophrenia by Takeda as a file.
02

Study summary

The primary purpose of this study is to determine if the long-term use of SPD489 (40, 80, 100, 120, 140, and 160mg) administered as a daily morning is safe and tolerable.

Read the detailed description

Not required

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Not Required
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 to 65 years of age
  • Has a reliable informant (eg, family member, social worker, caseworker, or nurse that spends >4 hours/week with the subject)
  • Fixed home/place of residence and can be reached by telephone
  • On a stable dose of antipsychotic medications
  • Able to swallow capsules

Exclusion criteria

Exclusion Criteria:

  • -Taking lithium, carbamazepine, lamotrigine, gabapentin, cholinesterase inhibitors, modafinil, or other stimulants such as methylphenidate and other amphetamine products
  • Treated with clozapine in past 30 days
  • Lifetime history of stimulant, cocaine, or amphetamine abuse or dependence
  • History of seizures (other than infantile febrile seizures), any tic disorder, or current diagnosis and/or a known family history of Tourette's Disorder, serious neurological disease, history of significant head trauma, dementia, cerebrovascular disease, Parkinson's disease, or intracranial lesions
  • Uncontrolled hypertension
  • History of thyroid disorder that has not been stabilized on thyroid medication
  • Glaucoma
  • Pregnant or nursing
  • Subject has received an product or participated in a clinical study within 30 days
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    SPD489

    Drug: SPD489

Interventions

  • DrugSPD489

    Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks

    Also known as: lisdexamfetamine dimesylate, LDX, Vyvanse

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Scores at 52 Weeks

    Time frame: Basline and 52 weeks

  2. Change From Baseline in Cognitive Test Battery (CogState Battery) Score at 52 Weeks

    Time frame: Baseline and 52 weeks

  3. Columbia-Suicide Severity Rating Scale (C-SSRS)

    Time frame: Up to 52 weeks

  4. Change From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) at 52 Weeks

    Time frame: Baseline and 52 weeks

  5. Change From Baseline in Simpson Angus Scale (SAS) Total Score at 52 Weeks

    Time frame: Baseline and 52 weeks

  6. Change From Baseline in Barnes Akathisia Scale (BAS) Total Score at 52 Weeks

    Time frame: Baseline and 52 weeks

  7. Change From Baseline in the Abnormal Involuntary Movement Scale (AIMS) at 52 Weeks

    Time frame: Baseline and 52 weeks

  8. Change From Baseline in Clinical Evaluation of Harmful Behavior (CEHB) Scale at 52 Weeks

    Time frame: Baseline and 52 weeks

  9. Change From Baseline in Amphetamine Cessation Symptom Assessment (ACSA) Total Score at 52 Weeks

    Time frame: Baseline and 52 weeks

Secondary outcomes

  1. Change From Baseline in Negative Symptom Assessment (NSA-16) Total Score at 52 Weeks

    Time frame: Baseline and 52 weeks

  2. Change From Baseline in the Personal and Social Performance (PSP) Scale Score at 52 Weeks

    Time frame: Baseline and 52 weeks

  3. Clinical Global Impression-Schizophrenia Severity of Illness (CGI-SCH-S) Scale

    Time frame: Baseline and week 52

  4. Clinical Global Impression-Schizophrenia Degree of Change (CGI-SCH-C) Scale

    Time frame: Up to 52 weeks

  5. Change From Baseline in Social Functioning Scale (SFS) at 52 Weeks

    Time frame: Baseline and 52 weeks

07

Results

Posted May 29, 2014
Limitations and caveats
Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized

Participant flow

Participant flow — Overall Study
MilestoneSPD489
Started0
Completed0
Not completed0

Outcome measures

PrimaryChange From Baseline in Positive and Negative Syndrome Scale (PANSS) Scores at 52 Weeks
Time frame:
Basline and 52 weeks

No measurements were reported for this outcome.

PrimaryChange From Baseline in Cognitive Test Battery (CogState Battery) Score at 52 Weeks
Time frame:
Baseline and 52 weeks

No measurements were reported for this outcome.

PrimaryColumbia-Suicide Severity Rating Scale (C-SSRS)
Time frame:
Up to 52 weeks

No measurements were reported for this outcome.

PrimaryChange From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) at 52 Weeks
Time frame:
Baseline and 52 weeks

No measurements were reported for this outcome.

PrimaryChange From Baseline in Simpson Angus Scale (SAS) Total Score at 52 Weeks
Time frame:
Baseline and 52 weeks

No measurements were reported for this outcome.

PrimaryChange From Baseline in Barnes Akathisia Scale (BAS) Total Score at 52 Weeks
Time frame:
Baseline and 52 weeks

No measurements were reported for this outcome.

PrimaryChange From Baseline in the Abnormal Involuntary Movement Scale (AIMS) at 52 Weeks
Time frame:
Baseline and 52 weeks

No measurements were reported for this outcome.

PrimaryChange From Baseline in Clinical Evaluation of Harmful Behavior (CEHB) Scale at 52 Weeks
Time frame:
Baseline and 52 weeks

No measurements were reported for this outcome.

PrimaryChange From Baseline in Amphetamine Cessation Symptom Assessment (ACSA) Total Score at 52 Weeks
Time frame:
Baseline and 52 weeks

No measurements were reported for this outcome.

SecondaryChange From Baseline in Negative Symptom Assessment (NSA-16) Total Score at 52 Weeks
Time frame:
Baseline and 52 weeks

No measurements were reported for this outcome.

SecondaryChange From Baseline in the Personal and Social Performance (PSP) Scale Score at 52 Weeks
Time frame:
Baseline and 52 weeks

No measurements were reported for this outcome.

SecondaryClinical Global Impression-Schizophrenia Severity of Illness (CGI-SCH-S) Scale
Time frame:
Baseline and week 52

No measurements were reported for this outcome.

SecondaryClinical Global Impression-Schizophrenia Degree of Change (CGI-SCH-C) Scale
Time frame:
Up to 52 weeks

No measurements were reported for this outcome.

SecondaryChange From Baseline in Social Functioning Scale (SFS) at 52 Weeks
Time frame:
Baseline and 52 weeks

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SPD489———

Baseline characteristics

Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized

Age, Categorical
Age, CategoricalSPD489
<=18 years—
Between 18 and 65 years—
>=65 years—
Sex: Female, Male
Sex: Female, MaleSPD489
Female—
Male—
Region of Enrollment
Region of EnrollmentSPD489
08

Study locations

2 sites
  • SP Research PLLC/Oklahoma Clinical Research Center
    Oklahoma City, Oklahoma 73112, United States
  • CRI Lifetree
    Philadelphia, Pennsylvania 19139, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2013 to primary completion in Apr 2013, 2 months.

Results were first posted in May 2014, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2013
First posted
Jan 4, 2013
StartActual
Feb 1, 2013
Primary completionActual
Apr 1, 2013
CompletionActual
Apr 1, 2013
Results first posted
May 29, 2014
Last update
Jun 22, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01760993
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Jan 4, 2013
Start date
Feb 1, 2013
Primary completion
Apr 1, 2013
Completion
Apr 1, 2013
Results posted
May 29, 2014
Last update
Jun 22, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisdexamfetamine

Start the discussion